WuXiPharmaTech, a research and development outsourcing company with operations in China and the United States, reports that the manufacturing facility of WuXi's wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA) passed an inspection by the US Food and Drug Administration (FDA) in July for the manufacture of the active pharmaceutical ingredient (API) for a branded commercial drug.

This represents the first FDA inspection of STA's facilities for the manufacture of an API. Last year, STA's manufacturing operations passed an inspection by the FDA for the manufacture of an advanced intermediate. Shanghai Syn-The-All Pharmaceutical Co. Ltd. provides development and manufacturing of small-molecule APIs and intermediates.
  
Source: WuXiPharmaTech